MedPath

7 Hills Pharma LLC

7 Hills Pharma LLC logo
🇺🇸United States
Ownership
Private
Established
1995-01-01
Employees
11
Market Cap
-
Website
http://www.7hillspharma.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1
Recruiting
Conditions
Pleural Mesothelioma
Renal Cell Cancer
Kidney Cancer
Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
ALK Genomic Tumor Aberrations
Melanoma
Advanced Cancer
Metastasis
Advanced Solid Tumor
Skin Cancer
Interventions
First Posted Date
2024-04-12
Last Posted Date
2024-11-25
Lead Sponsor
7 Hills Pharma, LLC
Target Recruit Count
126
Registration Number
NCT06362369
Locations
🇺🇸

Florida Cancer Specialists, Lake Mary, Florida, United States

🇺🇸

Dartmouth Hitchcock, Lebanon, New Hampshire, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Phase 1
Completed
Conditions
Solid Tumor
Interventions
Drug: 7HP349 Single Ascending Dose
Drug: Placebo Single Ascending Dose
Drug: Placebo Multiple Ascending Dose
Drug: 7HP349 Multiple Ascending Dose
Drug: 7HP349 Food Effect
First Posted Date
2020-08-11
Last Posted Date
2021-11-02
Lead Sponsor
7 Hills Pharma, LLC
Target Recruit Count
60
Registration Number
NCT04508179
Locations
🇺🇸

Frontage Clinical Services Inc., Secaucus, New Jersey, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.